Abstract
Inflammatory bowel diseases (IBD) are chronic intestinal disorders that are typically categorized as one of two subtypes: Crohn's disease (CD) and ulcerative colitis (UC). We have found that epigenetic regulator bromodomain-containing protein 4 (BRD4) is critical in controlling expression of IBD-associated inflammatory cytokine networks. Targeting BRD4 represents a novel therapeutic strategy by modulating IBD-associated inflammatory networks for effective treatment of IBD. Previously, we have successfully identified highly potent and specific BRD4 inhibitors which significantly suppressed colonic mucosal inflammation and chronicity in several animal models of IBD.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
